PVLA
Palvella Therapeutics, IncKey Statistics
About Palvella Therapeutics, Inc
Palvella Therapeutics, Inc. is a biotechnology company specializing in the development of groundbreaking therapies for rare genetic disorders, particularly those caused by specific gene mutations. Its lead investigational product aims to treat pachyonychia congenita, addressing significant unmet needs within this unique patient population. With a robust foundation in gene therapy, Palvella is committed to broadening its pipeline with innovative solutions designed to enhance patient quality of life. The company's strategic focus on research and development positions it to play a pivotal role in transforming the landscape of rare disease treatments, making it an appealing prospect for institutional investors.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | -92.10% |
| Return on Assets | -32.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $2.26 |
| Price-to-Book | 62.75 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $14.31M |
| Float | $9.27M |
| % Insiders | 17.66% |
| % Institutions | 74.03% |
Historical Volatility
Volatility is currently contracting